Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.

Conclusion: The recent approval of mogamulizumab represents an important addition to the armamentarium of pharmacotherapies for T-cell lymphomas.
PMID: 31648540 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - October 24, 2019 Category: Drugs & Pharmacology Authors: Moore DC, Elmes JB, Shibu PA, Larck C, Park SI Tags: Ann Pharmacother Source Type: research